P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease
暂无分享,去创建一个
L. Raymond | A. M. Kaufman | A. Milnerwood | Liang Wang | C. M. Gladding | Austen J. Milnerwood | Lynn A. Raymond | Liang Wang | Jing Fan | Clare M. Gladding | Lily Y.J. Zhang | Alexandra M. Kaufman | Jing Fan | Lily Y. J. Zhang
[1] L. Raymond,et al. N‐Methyl‐d‐aspartate receptor subunit‐ and neuronal‐type dependence of excitotoxic signaling through post‐synaptic density 95 , 2010, Journal of neurochemistry.
[2] Jing Fan,et al. Interaction of Postsynaptic Density Protein-95 with NMDA Receptors Influences Excitotoxicity in the Yeast Artificial Chromosome Mouse Model of Huntington's Disease , 2009, The Journal of Neuroscience.
[3] R. Pulido,et al. Differential interaction of the tyrosine phosphatases PTP-SL, STEP and HePTP with the mitogen-activated protein kinases ERK1/2 and p38alpha is determined by a kinase specificity sequence and influenced by reducing agents. , 2003, The Biochemical journal.
[4] C. Parsons,et al. Expression of Polyglutamine-expanded Huntingtin Induces Tyrosine Phosphorylation of N-Methyl-D-aspartate Receptors* , 2003, Journal of Biological Chemistry.
[5] S. Kaech,et al. Culturing hippocampal neurons , 2006, Nature Protocols.
[6] N. Chandel,et al. Mitochondrial ROS initiate phosphorylation of p38 MAP kinase during hypoxia in cardiomyocytes. , 2002, American journal of physiology. Lung cellular and molecular physiology.
[7] E. Nishida,et al. Activation and Involvement of p38 Mitogen-activated Protein Kinase in Glutamate-induced Apoptosis in Rat Cerebellar Granule Cells* , 1997, The Journal of Biological Chemistry.
[8] H. Bading,et al. Opposing roles of synaptic and extrasynaptic NMDA receptors in neuronal calcium signalling and BDNF gene regulation , 2003, Current Opinion in Neurobiology.
[9] H. Bading,et al. Synaptic Activity and Nuclear Calcium Signaling Protect Hippocampal Neurons from Death Signal-associated Nuclear Translocation of FoxO3a Induced by Extrasynaptic N-Methyl-d-aspartate Receptors* , 2010, The Journal of Biological Chemistry.
[10] Timothy H Murphy,et al. Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. , 2004, Journal of neurophysiology.
[11] N. Martin,et al. Intersectin enhances huntingtin aggregation and neurodegeneration through activation of c-Jun-NH2-terminal kinase. , 2007, Human molecular genetics.
[12] Yitao Liu,et al. Treatment of Ischemic Brain Damage by Perturbing NMDA Receptor- PSD-95 Protein Interactions , 2002, Science.
[13] L. Raymond,et al. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease , 2003, Neurobiology of Aging.
[14] J. Marshall,et al. Activation of MLK2-mediated Signaling Cascades by Polyglutamine-expanded Huntingtin* , 2000, The Journal of Biological Chemistry.
[15] S. Snyder,et al. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization , 1999, Nature Medicine.
[16] L. Raymond,et al. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models , 2006, Neurobiology of Disease.
[17] G. Landwehrmeyer,et al. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[18] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[19] D. Jane,et al. Native N-methyl-D-aspartate receptors containing NR2A and NR2B subunits have pharmacologically distinct competitive antagonist binding sites. , 2000, The Journal of pharmacology and experimental therapeutics.
[20] M. Hayden,et al. Inhibition of Calpain Cleavage of Huntingtin Reduces Toxicity , 2004, Journal of Biological Chemistry.
[21] Yamamura Ken-ichi,et al. Efficient selection for high-expression transfectants with a novel eukaryotic vector , 1991 .
[22] S. Larner,et al. p38 Map Kinase Mediates Bax Translocation in Nitric Oxide–Induced Apoptosis in Neurons , 2000, The Journal of cell biology.
[23] T. Nishi,et al. Immunocytochemical localization of the striatal enriched protein tyrosine phosphatase in the rat striatum: A light and electron microscopic study with a complementary DNA-generated polyclonal antibody , 1995, Neuroscience.
[24] L. Raymond,et al. Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease , 2004, Molecular and Cellular Neuroscience.
[25] L. Raymond,et al. Mitochondrial Sensitivity and Altered Calcium Handling Underlie Enhanced NMDA-Induced Apoptosis in YAC128 Model of Huntington's Disease , 2007, The Journal of Neuroscience.
[26] N. Déglon,et al. Implication of the JNK pathway in a rat model of Huntington's disease , 2009, Experimental Neurology.
[27] J. Diamond. A broad view of glutamate spillover , 2002, Nature Neuroscience.
[28] Angus C. Nairn,et al. Synaptic plasticity: one STEP at a time , 2006, Trends in Neurosciences.
[29] F. Pedata,et al. Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow , 2004, Neurobiology of Disease.
[30] J. Hodgson,et al. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. , 2001, American journal of human genetics.
[31] Q. Tang,et al. Glutamate signaling to ras-MAPK in striatal neurons , 2004, Molecular Neurobiology.
[32] L. Raymond,et al. Altered NMDA Receptor Trafficking in a Yeast Artificial Chromosome Transgenic Mouse Model of Huntington's Disease , 2007, The Journal of Neuroscience.
[33] G. Rumbaugh,et al. Distinct Synaptic and Extrasynaptic NMDA Receptors in Developing Cerebellar Granule Neurons , 1999, The Journal of Neuroscience.
[34] Y. Izumi,et al. Long‐term potentiation inhibition by low‐level N‐methyl‐D‐aspartate receptor activation involves calcineurin, nitric oxide, and p38 mitogen‐activated protein kinase , 2008, Hippocampus.
[35] J. Tsien,et al. In Vivo Evidence for NMDA Receptor-Mediated Excitotoxicity in a Murine Genetic Model of Huntington Disease , 2009, The Journal of Neuroscience.
[36] G. Wells,et al. Calpain inhibitors as potential treatment for stroke and other neurodegenerative diseases: recent trends and developments , 1998 .
[37] R. Huganir,et al. SynGAP regulates synaptic strength and mitogen-activated protein kinases in cultured neurons. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[38] S. Lipton,et al. Molecular pathways to neurodegeneration , 2004, Nature Medicine.
[39] Ann Marie Craig,et al. NMDA Receptor Subunits Have Differential Roles in Mediating Excitotoxic Neuronal Death Both In Vitro and In Vivo , 2007, The Journal of Neuroscience.
[40] James R. Burke,et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines , 2002, Nature Neuroscience.
[41] Ilya Bezprozvanny,et al. Deranged neuronal calcium signaling and Huntington disease. , 2004, Biochemical and biophysical research communications.
[42] Michael R. Hayden,et al. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease , 2008, Neurobiology of Disease.
[43] Marian DiFiglia,et al. Huntington Disease , 1998, Journal of neuropathology and experimental neurology.
[44] JaneR . Taylor,et al. The Striatal-Enriched Protein Tyrosine Phosphatase Gates Long-Term Potentiation and Fear Memory in the Lateral Amygdala , 2007, Biological Psychiatry.
[45] P. Kalivas,et al. The Role of AMPAR Trafficking Mediated by Neuronal Pentraxins in Cocaine-induced Neuroadaptations. , 2009, Molecular and cellular pharmacology.
[46] R. Duncan,et al. Specific Targeting of Pro-Death NMDA Receptor Signals with Differing Reliance on the NR2B PDZ Ligand , 2008, The Journal of Neuroscience.
[47] L. Raymond,et al. Polyglutamine-Modulated Striatal Calpain Activity in YAC Transgenic Huntington Disease Mouse Model: Impact on NMDA Receptor Function and Toxicity , 2008, The Journal of Neuroscience.
[48] J. Haddad. N-methyl-d-aspartate (NMDA) and the regulation of mitogen-activated protein kinase (MAPK) signaling pathways: A revolving neurochemical axis for therapeutic intervention? , 2005, Progress in Neurobiology.
[49] L. Ellerby,et al. Calpain Activation in Huntington's Disease , 2002, The Journal of Neuroscience.
[50] R. Yasuda,et al. Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. , 2003, Brain : a journal of neurology.
[51] M. M. Soundarapandian,et al. DAPK1 Interaction with NMDA Receptor NR2B Subunits Mediates Brain Damage in Stroke , 2010, Cell.
[52] M. Segal,et al. Formation of dendritic spines in cultured striatal neurons depends on excitatory afferent activity , 2003, The European journal of neuroscience.
[53] I. Bezprozvanny,et al. HAP1 facilitates effects of mutant huntingtin on inositol 1,4,5‐trisphosphate‐induced Ca2+ release in primary culture of striatal medium spiny neurons , 2004, The European journal of neuroscience.
[54] G. Hardingham. Pro-survival signalling from the NMDA receptor. , 2006, Biochemical Society transactions.
[55] Ming Liu,et al. Calpain in the CNS: From Synaptic Function to Neurotoxicity , 2008, Science Signaling.
[56] K. Roche,et al. Molecular determinants of NMDA receptor internalization , 2001, Nature Neuroscience.
[57] R. Llinás,et al. Disturbed Ca 2 signaling and apoptosis of medium spiny neurons in Huntington ’ s disease , 2005 .
[58] G. Westbrook,et al. The Incorporation of NMDA Receptors with a Distinct Subunit Composition at Nascent Hippocampal Synapses In Vitro , 1999, The Journal of Neuroscience.
[59] E. Waxman,et al. N-methyl-D-aspartate Receptor Subtypes: Multiple Roles in Excitotoxicity and Neurological Disease , 2005, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[60] H. Niwa,et al. Efficient selection for high-expression transfectants with a novel eukaryotic vector. , 1991, Gene.
[61] L. Raymond,et al. Early Increase in Extrasynaptic NMDA Receptor Signaling and Expression Contributes to Phenotype Onset in Huntington's Disease Mice , 2010, Neuron.
[62] Rand Askalan,et al. Tyrosine Phosphatase STEP Is a Tonic Brake on Induction of Long-Term Potentiation , 2002, Neuron.
[63] K. Nikolich,et al. Regulation of NMDA receptor trafficking and function by striatal‐enriched tyrosine phosphatase (STEP) , 2006, The European journal of neuroscience.
[64] Claire-Anne Gutekunst,et al. A YAC Mouse Model for Huntington’s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration , 1999, Neuron.
[65] L. Raymond,et al. Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease , 2002, Neuron.
[66] Michael R. Hayden,et al. Mutant Huntingtin Enhances Excitotoxic Cell Death , 2001, Molecular and Cellular Neuroscience.
[67] G. Hardingham,et al. The Dichotomy of NMDA Receptor Signaling , 2007, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[68] P. Wahle,et al. Cellular and molecular characterization of a brain-enriched protein tyrosine phosphatase , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[69] Francesc X. Soriano,et al. Compartmentalized NMDA receptor signalling to survival and death , 2007, The Journal of physiology.
[70] M. Tymianski,et al. Molecular mechanisms of calcium-dependent excitotoxicity , 2000, Journal of Molecular Medicine.
[71] J. Bibb,et al. Extrasynaptic NMDA Receptors Couple Preferentially to Excitotoxicity via Calpain-Mediated Cleavage of STEP , 2009, The Journal of Neuroscience.
[72] C. Kuo,et al. Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires ICE/CED-3 family proteases , 1997, Molecular and cellular biology.
[73] L. Raymond,et al. Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load , 2007, The Journal of physiology.
[74] Z. Xiong,et al. Differential Roles of NR2A- and NR2B-Containing NMDA Receptors in Activity-Dependent Brain-Derived Neurotrophic Factor Gene Regulation and Limbic Epileptogenesis , 2007, The Journal of Neuroscience.
[75] R. Huganir,et al. SynGAP: a Synaptic RasGAP that Associates with the PSD-95/SAP90 Protein Family , 1998, Neuron.
[76] Surojit Paul,et al. NR2B‐NMDA receptor mediated modulation of the tyrosine phosphatase STEP regulates glutamate induced neuronal cell death , 2010, Journal of neurochemistry.
[77] A. Buisson,et al. Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[78] L. Raymond,et al. Subtype‐Specific Enhancement of NMDA Receptor Currents by Mutant Huntingtin , 1999, Journal of neurochemistry.
[79] E. Simpson,et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. , 2003, Human molecular genetics.
[80] S. Harper,et al. MAPKs: new targets for neurodegeneration , 2003, Expert opinion on therapeutic targets.
[81] Angus C. Nairn,et al. NMDA-mediated activation of the tyrosine phosphatase STEP regulates the duration of ERK signaling , 2003, Nature Neuroscience.
[82] Carlos Cepeda,et al. Enhanced sensitivity to N‐methyl‐D‐aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease , 1999, Journal of neuroscience research.
[83] R. Llinás,et al. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[84] S. Vincent,et al. Neurotransmitter regulation of MAP kinase signaling in striatal neurons in primary culture , 1998, Synapse.
[85] J. Rosenblatt,et al. Age-associated changes in SAPK/JNK and p38 MAPK signaling in response to the generation of ROS by 3-nitropropionic acid , 2003, Mechanisms of Ageing and Development.
[86] Roberto Malinow,et al. Subunit-Specific NMDA Receptor Trafficking to Synapses , 2002, Neuron.
[87] L. Mao,et al. Regulation of mitogen‐activated protein kinases by glutamate receptors , 2007, Journal of neurochemistry.
[88] S. Hyman,et al. Glutamate, But Not Dopamine, Stimulates Stress-Activated Protein Kinase and AP-1-Mediated Transcription in Striatal Neurons , 1997, The Journal of Neuroscience.
[89] H. Bading,et al. The Yin and Yang of NMDA receptor signalling , 2003, Trends in Neurosciences.
[90] P. Calabresi,et al. Mutant huntingtin goes straight to the heart , 2002, Nature Neuroscience.
[91] T. Herdegen,et al. c-Jun N-Terminal Protein Kinase (JNK) 2/3 Is Specifically Activated by Stress, Mediating c-Jun Activation, in the Presence of Constitutive JNK1 Activity in Cerebellar Neurons , 2002, The Journal of Neuroscience.
[92] L. Raymond,et al. Selective neuronal degeneration in Huntington's disease. , 2006, Current topics in developmental biology.
[93] J. Macdonald,et al. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. , 1999, Science.
[94] C. Hsieh,et al. The effect of aging on p38 signaling pathway activity in the mouse liver and in response to ROS generated by 3-nitropropionic acid , 2002, Mechanisms of Ageing and Development.